Tempest Therapeutics reports preliminary approval of OvaScience derivative settlement

Tempest Therapeutics, Inc.

Cima v. Dipp derivative lawsuit settlement received preliminary court approval on March 23, 2023.
Upon final approval of the Cima settlement, a motion to dismiss the related Chiu v. Dipp action will be filed.
Settlement involves claims against OvaScience (predecessor) and former officers for alleged breach of fiduciary duties.
Settlement terms are described in a notice available on Tempest's investor website.
Litigation stems from OvaScience's January 2015 follow-on public offering.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.